ALCEDIAG (subsidiary of ALCEN) operates as a specialized medicine company dedicated to advancing the field of diagnostics through the development of biological signatures. Focusing primarily on mental health, the company specializes in biomarkers derived from the analysis of RNA editing, an epigenetic mechanism that alters the structure and conformation of RNA. This process can result in the production of modified protein forms or changes in gene expression regulation. RNA editing may be modulated in certain diseases or as a response to medical treatments. Specifically, ALCEDIAG’s solution EDITOX assesses the risk of drugs inducing severe psychiatric side effects, with an initial focus on depression and suicide, followed by an expansion to epilepsy.